Adherence

High cost or insurance-related barriers are the primary drivers of discontinuation for obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice, accounting for nearly half of all early and late discontinuations.

If you are stopping semaglutide or tirzepatide, the most likely reason is cost or insurance issues, not that the drug didn't work. Check your insurance coverage, look for manufacturer coupons, and talk to your doctor about financial assistance programs before assuming the treatment is unsuitable for you.